Arvinas Inc (NAS:ARVN)
$ 34.86 -0.37 (-1.05%) Market Cap: 2.39 Bil Enterprise Value: 1.24 Bil PE Ratio: 0 PB Ratio: 3.90 GF Score: 65/100

Arvinas Inc at Cowen Health Care Conference (Virtual) Transcript

Mar 07, 2022 / 02:10PM GMT
Release Date Price: $61.23 (-5.13%)
Tyler Van Buren
Cowen and Company, LLC - Analyst

Great. Good morning, everyone. Welcome to the first day of Cowen's 42nd annual healthcare conference. My name is Tyler Van Buren. I'm a senior biotech analyst at Cowen. For this session, we will fireside chat with Arvinas. It is my pleasure to introduce Ian Taylor, the Chief Scientific Officer. Ian, thank you very much for being here with us.

Ian Taylor
Arvinas, Inc - Chief Scientific Officer

It's my pleasure, Tyler. Thanks very much for your invitation.

Tyler Van Buren
Cowen and Company, LLC - Analyst

Sure. (Conference Instructions) So with that, we'll go ahead and get started with the lead program, ER degrader, ARV-471.

Questions & Answers

Tyler Van Buren
Cowen and Company, LLC - Analyst

So Ian, the latest update on the Phase 1 dose escalation study at San Antonio Breast showed consistently strong efficacy data in two times the number of patients, and a 40% clinical benefit rate. So with the expansion

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot